Capricor Therapeutics is trading 5.6% down at $6.24, with no clear company-specific news explaining the October 21 decline. - Recent coverage highlighted positive long-term Deramiocel data, but did not establish it as a cause of this drop. - The supplied sector context shows biotech rising, while broader index moves are mixed and mostly modest; those signals do not clearly explain the decline.